Finder's Pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Cellular Biomedicine Group is a biotechnology business based in the US. Cellular Biomedicine Group stocks (CBMG.US) are listed on the NASDAQ and all prices are listed in US Dollars. Cellular Biomedicine Group employs 217 staff and has a trailing 12-month revenue of around $322,950.
|52-week range||$17.60 - $19.76|
|50-day moving average||$18.91|
|200-day moving average||$18.44|
|Wall St. target price||$19.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-2.32|
Note: The dollar amounts in the table below are in Canadian dollars.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|Gross profit TTM||$277,542|
|Return on assets TTM||-34.66%|
|Return on equity TTM||-129.91%|
|Market capitalisation||$384.7 million|
TTM: trailing 12 months
We're not expecting Cellular Biomedicine Group to pay a dividend over the next 12 months.
Cellular Biomedicine Group's shares were split on a 1:100 basis on 30 January 2013. So if you had owned 100 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cellular Biomedicine Group shares – just the quantity. However, indirectly, the new 9900% higher share price could have impacted the market appetite for Cellular Biomedicine Group shares which in turn could have impacted Cellular Biomedicine Group's share price.
Over the last 12 months, Cellular Biomedicine Group's shares have ranged in value from as little as $17.6 up to $19.755. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cellular Biomedicine Group's is 1.2092. This would suggest that Cellular Biomedicine Group's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Cellular Biomedicine Group, Inc. , a clinical stage biopharmaceutical company, develops immunotherapies for cancer and stem cell therapies for degenerative diseases in Greater China. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for treating a range of cancer indications comprising technologies in chimeric antigen receptor modified T cells (CAR-T), T-cells with genetically modified, tumor antigen-specific T-cell receptors, and next generation neoantigen-reactive bio-markers based tumor infiltrating lymphocytes; and human adipose-derived mesenchymal progenitor cells for the treatment of joint diseases The company's CAR-T products include CD20 for use in anti-tumor activities; CD22, a surface maker highly expressed in B cell malignancies in hairy cell leukemia; and B-cell maturation antigen therapies for treating refractory multiple myeloma in patients. It also develops NKG2D CAR therapies for use in NK cell signaling; alpha fetoprotein TCR-T therapies for treating hepatocellular carcinoma; tumor infiltrating lymphocyte therapies for treating immunogenic cancers; and knee osteoarthritis therapies, including AlloJoin therapy, which is in a Phase II clinical trial, as well as Re-Join that has completed the Phase IIb clinical trial. In addition, it engages in biopharmaceutical businesses, including research and development, technical support, technical service, and technology transfer activities in biomedical technology field; manufacturing non-food, pharmaceutical polypeptides, and medical devices; and the wholesale of cosmetics, sanitary products, and biological agents. The company has a collaboration agreement with Novartis Pharma AG to manufacture and supply their CAR-T cell therapy Kymriah in China. Cellular Biomedicine Group, Inc.
Steps to owning and managing HAE stock, with 24-hour and historical pricing before you buy.
Use Go Auto to shop for new or used vehicles from multiple dealerships, with no hidden fees and access to bad credit financing.
Steps to owning and managing Aritzia (ATZ) stock, with 24-hour and historical pricing before you buy.
Get low fees and access many different types of accounts, platforms and investments with this reputable online broker.
Read our expert analysis on Hifi Finance and how the token will perform in the future.
Read our expert analysis on Kusama and how the token will perform in the future.
This guide provides step-by-step instructions on how to buy The Sandbox, lists some exchanges where you can get it and provides daily price data on SAND.
We’ve rounded up stats on some of the most popular COVID testing stocks, along with information on how they compare and how to invest.
This guide explores the different ways of buying Shiba Inu on a cryptocurrency exchange as well as where you should store your cryptocurrency.
This guide provides step-by-step instructions on how to buy Baby Doge Coin, lists some exchanges where you can get it and provides daily price data on BABYDOGE.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.